β-Blockers and Cardiac Events in Noncardiac Surgery Lessons from DECREASE-IV M Chadi Alraies, MD Department of Hospital Medicine Grand Round Cleveland Clinic Foundation
M C Alraies
1
Agenda • • • •
Perioperative cardiac events RCRI ACC/AHA Guidelines for perioperative BB use. What is already known about perioperative βblockers • Literature review • DECREASE-IV study M C Alraies
2
Introduction • About 20 million Americans undergo surgery with general anesthesia each year.1 • Cardiac events (MI or Cardiac death) result in perioperative mortality rate of 3-6%
1. July 20, 2005 Los Angeles Times
M C Alraies
3
Incidence of Perioperative Myocardial Infarction After Noncardiac Surgery Goldman et al. NEJM 1977
5.8%
Mangano et al. NEJM 1990
3.0% perioperative MI
Shah et al. Anesth Analg 1990
4.7-5.6% in patients with known coronary disease
Ashton et al., Ann Intern Med 1993
1.8% perioperative MI in men over the age of 40
Mangano et al., NEJM 1995
1.4%, 3.2%, to 6.9% in successive surgical patients
Deveraux et al., CMAJ 2005
~3%
Deveraux et al., Lancet 2008
non-fatal MI in POISE trial in the placebo group was 5.1% at 30 days.
M C Alraies
4
Perioperative cardiac events • The most common reason for preoperative evaluation. • Associated with increased mortality and results in higher costs
M C Alraies
5
Prognosis of perioperative MI after noncardiac surgery
• 15-25% in-hospital mortality, of which perioperative MI accounts for 2/3 • Nonfatal perioperative MI predisposes to death, ACS, or progressive angina: – Post-op troponin I > 1.5 mcg/L: increased 6-mo mortality (OR 5.9) – Post-op troponin I > 0.6 mcg/L: increased 32-mo mortality (OR 2.15)
M C Alraies
6
Pathophysiology of Perioperative MI • Multifactorial • Myocardial oxygen demand/supply mismatch due to: – Perioperative surgical stress – Tachycardia – Hypertension – Pain
• Coronary plaque instability and subsequent rupture also lead to infarction. M C Alraies
7
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC/AHA Guideline JACC 2007;50:159-241
M C Alraies
8
Revised Cardiac Risk Index (RCRI) Five independent predictors of major cardiac complications* History of ischemic heart disease History of compensated or prior HF History of cerebrovascular disease Diabetes mellitus requiring treatment with insulin Preoperative serum creatinine >2.0 mg/dL (177 mol/L) Rate of cardiac death, nonfatal myocardial infarction, and nonfatal cardiac arrest according to the number of predictors ¥ No risk factors - 0.4 percent (95% CI 0.1-0.8 percent) One risk factor - 1.0 percent (95% CI 0.5-1.4 percent Two risk factors - 2.4 percent (95% CI 1.3-3.5 percent Three or more risk factors - 5.4 percent (95% CI 2.8-7.9 percent)
M C Alraies
9
M C Alraies
10
Applying Classification of Recommendations and Level of Evidence Level A
Multiple (3-5) population risk strata evaluated Level B
Limited (2-3) population risk strata evaluated
Class I
Class IIa
Class IIb
Class III
• Recommen• Recommendation that dation in favor of procedure or treatment or treatment is procedure being useful/ effective useful/ effective • Sufficient • Some conflicting evidence from evidence from multiple multiple randomized trials randomized trials or meta-analyses or meta-analyses
• Recommendation’s usefulness/ efficacy less well established • Greater conflicting evidence from multiple randomized trials or meta-analyses
• Recommendation that procedure or treatment not useful/effective and may be harmful • Sufficient evidence from multiple randomized trials or meta-analyses
Class I
Class IIa
Class IIb
Class III
Benefit >>> Risk
Benefit >> Risk Additional studies with focused objectives needed
Benefit ≥ Risk Additional studies with broad objectives needed; Additional registry data would be helpful
Risk ≥ Benefit No additional studies needed
SHOULD be performed/ administered
IT IS REASONABLE to perform procedure/ administer M C Alraies
MAY BE CONSIDERED
SHOULD NOT NOT HELPFUL 11 MAY BE HARMFUL
Level C
Very limited (1-2) population risk strata evaluated
What it means
ACC/AHA Recommendation for Beta Blockers •
•
•
•
Class I – Patients on BB should remain on these agents [level C] – BB should be given to patients undergoing vascular surgery who are at high cardiac risk owing to the finding of ischemia on preop testing [level B] Class IIa – BB probably recommend those undergoing vascular surgery preop testing notes CHD [level B] – BB probably recommend high cardiac risk with more than 1 clinical risk factor [level B] – BB probably recommend preop assessment identifies CHD or high cardiac risk with > 1 risk factor and undergoing intermediate risk surgery or vascular surgery [level B] Class IIb – BB uncertain in patient with a single risk factor undergoing intermediate or vascular surgery [level C] – BB uncertain in patient with no risk factors undergoing vascular surgery [level B] Class III – Beta blockers should not be given to patients undergoing surgery who have absolute contraindications to beta blockade. [level C]
ACC/AHA Guideline JACC 2007;50:159-241
M C Alraies
12
ACC/AHA Recommendation for Beta Blockers
ACC/AHA Guideline JACC 2007;50:159-241
M C Alraies
13
ACC/AHA guidelines Recommendations for Statin Therapy CLASS I • For patients currently taking statins and scheduled for noncardiac surgery, statins should be continued. (B) CLASS IIa • For patients undergoing vascular surgery with or without clinical risk factors, statin use is reasonable. (B) CLASS IIb • For patients with at least 1 clinical risk factor who are undergoing intermediate-risk procedures, statins may be considered. (C) ACC/AHA Guideline JACC 2007;50:159-241
M C Alraies
14
Perioperative β-Blockers
M C Alraies
15
Mechanism of Beta-blockers? • Decrease myocardial oxygen demand – Heart rate – Myocardial contractility
• • • •
Reduce the adrenergic activity Reduce levels of free fatty acid Increase myocardial glucose uptake Coronary plaque stability – requires weeks – Anti-inflammatory – Progression of atherosclerosis M C Alraies
16
● Most trials are inadequately powered. ● Few randomized trials of medical therapy to prevent perioperative MACE have been performed. ● Few randomized trials have examined the role of perioperative beta-blocker therapy, and there is particularly a lack of trials that focus on high-risk patients. ● Studies to determine the role of beta blockers in intermediate- and low-risk populations are lacking. ● Studies to determine the optimal type of beta blockers are lacking. ● No studies have addressed care-delivery mechanisms in the perioperative setting, identifying how, when, and by whom perioperative beta-blocker therapy should be implemented and monitored. M C Alraies
17
Review of literature
M C Alraies
18
Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery. Mangano 1996
Participants
200 patients.
Surgery
Elective non-cardiac surgery
Intervention
Atenolol (100mg PO or 10 IV) vs. placebo
Administration
Before anesthesia & Immediately after surgery for 7 days
Median follow-up
24 months
Primary outcome
composite all-cause mortality, MI, UA, CHF
Mangano DT, Layug EL, Wallace A, et al; for Multicenter Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and M C Alraies 19 cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996;335:1713–1720.
Mangano 1996 83% 68%
P = 0.008
Overall Survival in the Two Years after Noncardiac Surgery among 192 Patients in the Atenolol and Placebo Groups Who Survived to Hospital Discharge. Mangano DT. N Engl J Med. 1996;335:1713–1720.
M C Alraies
20
Mangano 1996 90% 79%
Event-free Survival in the Two Years after Noncardiac Surgery among 192 Patients in the Atenolol and Placebo Groups Who Survived to Hospital Discharge. N Engl J Med. 1996;335:1713–1720. Mangano DT, N Engl J Med. 1996;335:1713–1720.
M C Alraies
21
Mangano 1996 • In patients who have or are at risk for CAD + noncardiac surgery, treatment with atenolol reduce mortality and the incidence of MACE for two years after surgery.
Mangano DT, N Engl J Med. 1996;335:1713–1720.
M C Alraies
22
The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery Poldermans D 1999 Participants
112 patients.
Stress test
Positive dobutamine echocardiography
Surgery
Elective non-cardiac surgery
Intervention
Bisoprolol (5 mg titrated to 10mg) vs. placebo
Administration
Daily for 1 week before surgery and QD for 30 days post surgery.
Dose titration
Yes (1 week interval)
Median follow-up
24 months
Primary outcome
composite all-cause mortality, MI, UA, CHF
Poldermans D, Boersma E, Bax JJ, et al; for Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999;341: 1789–1794.
M C Alraies
23
Poldermans D,1999
Kaplan–Meier Estimates of the Cumulative Percentages of Patients Who Died of Cardiac Causes or Had a Nonfatal Myocardial Infarction during the Perioperative Period. Poldermans D,. N Engl J Med. 1999;341: 1789–1794.
M C Alraies
24
Poldermans D,1999
Bisoprolol reduces the perioperative incidence of death from cardiac causes and nonfatal myocardial infarction in high-risk patients who are undergoing major vascular surgery.
Poldermans D,. N Engl J Med. 1999;341: 1789–1794.
M C Alraies
25
β-Blockers and Reduction of Cardiac Events in Noncardiac Surgery, scientific review. Auerbach 2002
Auerbach AD, Goldman L. Beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA. 2002;287:1435–1444
M C Alraies
26
1. β-blockers work the best in high risk patients. 2. Need more studies for patients with stable coronary disease and are undergoing elective surgery? 3. What is the optimal duration of therapy? 4. Which agent is the best? 5. When to start BB therapy?
M C Alraies
Auerbach AD. JAMA. 2002;287:1435–144427
Perioperative -blockade (POBBLE) for patients undergoing infrarenal vascular surgery: Results of a randomized double-blind controlled trial. Brady et al 2005, UK
Participants
103 patients – median age 73 yrs
Surgery
Infrarenal vascular surgery
Intervention
Metoprolol (50 mg BID) vs. Placebo
Administration
Day before surgery twice daily & Continued for 7-14 days
Dose titration
No
Median follow-up
30 days
Primary outcome
composite all-cause mortality, MI, UA, CHF
Brady AR, Gibbs JS, Greenhalgh RM, et al. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. J Vasc Surg. 2005;41:602– 609.
M C Alraies
28
POBBLE trial 2005 • lower-risk vascular surgical patients, perioperative β-blockade does not reduce 30day cardiovascular morbidity and mortality but, facilitate earlier patient discharge.
Brady AR. J Vasc Surg. 2005;41:602– 609.
M C Alraies
29
The effects of perioperative betablockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Yang et al 2006
Participants
500 vascular patients – mean age 66 yrs
Surgery
Vascular surgery only
Intervention
Metoprolol (50-100mg) vs. placebo
Administration
2 hours before anesthesia induction then daily for 5 days.
Dose titration
No
Median follow-up
30 days and 6 months
Primary outcome
composite all-cause mortality, MI, UA, CHF
Yang H, Raymer K, Butler R, et al. The effects of perioperative betablockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J. 2006;152:983–990 30
M C Alraies
Outcomes at 30 days postoperative
Yang H. Am Heart J. 2006;152:983–990
M C Alraies
31
Cumulative risk primary outcomes at 6 months.
Yang H. Am Heart J. 2006;152:983–990
M C Alraies
32
MaVS trial 2006
• Metoprolol has no effect in reducing the cardiac event rate in vascular patients at 30 days postoperative or at 6 months.
Yang H. Am Heart J. 2006;152:983–990
M C Alraies
33
Pooled RRR of all four trials
Yang H. Am Heart J. 2006;152:983–990
M C Alraies
34
Effect of perioperative blockade in patients with diabetes undergoing major non-cardiac surgery: randomized placebo controlled, blinded multicentre (DIPOM) trial Participants
921 diabetic patients.
Surgery
Major (over 1 hr) non-cardiac surgery (majority orthopedic)
Mean age
64 yrs
Intervention
Metoprolol XL 50 mg day before surgery Metoprolol XL 100 mg 2 hours before induction, then Metoprolol XL 100 mg daily x 8 days.
Administration
Day of surgery for 8 days post op
Titration of therapy
No
Median follow-up
18 months
Primary outcome
composite all-cause mortality, MI, UA, CHF
Comment
Followed Mangano’s inclusion criteria and protocol. (2.5 x bigger sample size)
Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomized placebo controlled, blinded multicentre trial. BMJ. 2006;332:1482.
M C Alraies
35
Kaplan-Meier plot of time to primary outcome measure
Juul AB. DIPOM. BMJ. 2006;332:1482.
36 M C Alraies
Diabetic Postoperative Mortality and Morbidity (DIPOM) 2006 • Heart rate lower with metoprolol (72 vs 78 bpm) • Primary outcome: 21% metoprolol group vs. 20% placebo group • Metoprolol XL (100 mg a day for up to eight perioperative days) for diabetics does not affect long term mortality and cardiac morbidity. (But wide CI) Juul AB. DIPOM. BMJ. 2006;332:1482.
M C Alraies
37
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial)
Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomized controlled trial. Lancet. 2008;371:1839 –1847.
M C Alraies
38
PeriOperative Ischemia Evaluation (POISE) Participants
8351 patients. Hx: CAD, PVD, CVA, CHF within 3 yrs of surgery, or vascular surgery
Surgery
Major non-cardiac surgery – majority vascular surgeries
Mean age
69 yrs
Intervention
Metoprolol XL 100 mg 2-4 hours before induction Metoprolol XL 100 mg 0-6 hours after surgery Metoprolol XL 200 mg daily for 30 days following surgery Metoprolol 15mg IV every 6 hours if NPO
Administration
Day of surgery & for 8 days post op
Median follow-up
18 months
Titration of therapy
No
Primary outcome
composite all-cause mortality, MI, UA, CHF
Comment
75 centers, 9 countries Goal 10000 patients (final enrollment 8351)
Devereaux PJ, (POISE trial). Lancet. 2008;371:1839 –1847.
39 M C Alraies
Effects of study treatment on primary and secondary outcomes at 30 days 8351 Patients Hx: CAD, PVD, CVA, CHF Major vascular surgery
4174 Patients Metoprolol XL 100mg 2-4 hours before surgery and
4177 Patients Placebo
200mg/day for 30 days
Cardiovascular death, nonfatal myocardial infarction, or non-fatal cardiac arrest
Cardiovascular death, nonfatal myocardial infarction, or non-fatal cardiac arrest
5.8%
6.9%
Total mortality
Total mortality
3.1%
2.3%
Stroke 1%
Stroke 0.5%
Non-fatal stroke 0.6%
Non-fatal stroke 0.3% M C Alraies
Devereaux PJ,. Lancet. 2008;371:1839 –1847.
40
Kaplan-Meier estimates of the primary outcome (A), myocardial infarction (B), stroke (C), and death (D)
Primary
MIs
Primary
MIs
Death
Strokes
Strokes
Death
Devereaux et al. POISE . Lancet. 2008;371:1839 –1847.
M C Alraies
41
PeriOperative Ischemia Evaluation (POISE)
BB prevents 15 MI 3 Revasc 7 Atrial Fib
BB causes: 8 Deaths 5 Stroke (1.0% vs. 0.5%, HR 2.17, p = 0.005) 53 Hypotension (15.0% vs. 9.7%, p < 0.0001) 42 Bradycardia (6.6% vs. 2.4%, p < 0.0001) Devereaux et al. POISE . Lancet. 2008;371:1839 –1847.
M C Alraies
42
POISE observations • BB decreased non-fatal MI and CV mortality • Evidence does not support initiation of BB in most pts undergoing surgery with (RCRI <3) • Benefit of BB for: – High risk patients (RCRI 3+) – Pts with evidence of ischemia by stress testing
• However, most patients at highest CV risk have independent indications for B-B therapy M C Alraies
43
POISE limitations • Significant hypotension more often in BB group (15% vs. 9.7%) • Fixed dose, not titrated • Started treatment only 2-4 hrs prior to surgery • High starting dose of oral metoprolol may have contributed to hypotension/stroke rate.
M C Alraies
44
Bisoprolol and Fluvastatin for the Reduction of Perioperative Cardiac Mortality and Myocardial Infarction in Intermediate-Risk Patients Undergoing Noncardiovascular Surgery A Randomized Controlled Trial (DECREASE-IV) Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van Poorten F, Bax JJ, Thomson IR, Poldermans D; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Departments of Vascular Surgery, Erasmus Medical Centre, Rotterdam, the Netherlands. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
45
Objective • This study evaluated the beta-blockers and statins for the prevention of perioperative cardiovascular events in intermediate-risk patients undergoing noncardiovascular surgery.
Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
46
DECREASE-IV Participants
1066 patients. Risk for a perioperative MACE 1-6% (RCRI 2-3)
Surgery
elective noncardiovascular surgery
Mean age
65 yrs
Intervention
Bisoprolol starting at 2.5 mg po daily Dose modified by 1.25 or 2.5 mg per day Maximum dose of 10 mg po dialy Metoprolol IV every 6 hours if NPO Fluvastatin XL 80 mg po daily (NGT if unable to swallow)
Administration
Median 34 days before surgery & 30 days after surgery
Median follow-up
30 days
Titration of therapy
Yes (Target: heart rate of 50-70 bpm)
Primary end point
Cardiac death, all-cause mortality, non-fatal MI
Secondary end point Cardiac arrhythmias, Acute heart failure, Coronary revascularization Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
47
Methods • • • • •
A prospective Open-label 2 x 2 factorial design Multicenter Randomized Controlled trial
Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
48
Safety End Points • Stroke • Significant bradycardia & hypotension • Significant liver and muscles markers – ALT 3 times upper limit of normal – CK level more than 10 times upper limit of normal – Myopathy – Rhabdomyolysis
Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
49
Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
50
Incidence of primary study end point by treatment group
Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
M C Alraies
51
M C Alraies Dunkelgrun al. DECREASE-IV. Annals of Surgery. 2009 Jun;249(6):921-6.
52
Limitations • Majority of patients (RCRI 2-3) had an independent indication for beta-blockade prior to surgery • Early termination for slow recruitment – 78% of the patient who met the inclusion criteria were already on beta-blockers and/or statin
• Only 1% of the study population were actually titrated. • Not blinded: Beta-blocker therapy cannot be titrated to heart rate M C Alraies
53
POISE
DECREASE - IV
Type of BB
Metoprolol XL
Bisoprolol
Starting dose
100 mg 2 hours preop Then 200 mg daily
2.5 mg daily 30 days Preop Titrated to 10 mg po daily
Initiation time
1 day
30 days
Dose titration
No
Yes (only in 1%)
Dose adjustment for HR
No
yes
Withdrawal of therapy
Early (7 days)
Late (30 days)
Sample size
8351
1066
Age (mean)
69 yrs
65 yrs
Type of surgery
Non-cardiac
Non-cardiovascular
M C Alraies
54
Thank you M C Alraies
55
Questions
M C Alraies
56